Enanta Pharmaceuticals (NASDAQ: ENTA)
Enanta Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Enanta Pharmaceuticals Company Info
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
News & Analysis
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.
Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales
The small drugmaker depends on royalties from HCV drug Mavyret. And those sales aren't as strong as they used to be.
This Small Biotech Is Building on a Surprising Success
Enanta Pharmaceuticals helped AbbVie score big last year. Now it's setting its sights even higher.
The Best Deals in Under-the-Radar Stocks
Anyone can buy a household brand-name stock, but sometimes the best gems fly under Wall Street's radar.
3 Biotech Stocks to Buy As the Greek Tragedy Unfolds
Exelixis, Enanta Pharmaceuticals, and Isis Pharmaceuticals are three names in biotech I'm closely watching in case they fall as a result of the financial crisis in Greece.
3 Beaten Down Healthcare Stocks Poised for a Turnaround
They're beaten down, but these 3 healthcare stocks just might be ready to bounce back.
Does This Small Biotech Have the Making of a Blockbuster?
Three Fools think these emerging biotech stocks could have a blockbuster drug in the making.
3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.
Gilead's nearly 46% profit margin is among the best in the biotech sector. However, these three biotech stocks currently have Gilead beat.
Valuation
Earnings Transcripts
Enanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcript
ENTA earnings call for the period ending June 30, 2022.
Enanta Pharmaceuticals (ENTA) Q2 2022 Earnings Call Transcript
ENTA earnings call for the period ending March 31, 2022.
Enanta Pharmaceuticals (ENTA) Q1 2022 Earnings Call Transcript
ENTA earnings call for the period ending December 31, 2021.
Enanta Pharmaceuticals, inc (ENTA) Q4 2021 Earnings Call Transcript
ENTA earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.